Cannabis Report
Home > Boards > US Listed > Medical - Drugs >

Imprimis Pharmaceuticals Inc (IMMY)

Add IMMY Price Alert      Hide Sticky   Hide Intro
Search This Board: 
Last Post: 4/11/2018 7:12:55 AM - Followers: 63 - Board type: Free - Posts Today: 0

Imprimis Pharmaceuticals, Inc.

Oct 22, 2015. Last month, Turing Pharmaceuticals LLC, the sole supplier of Daraprim, increased the price of this prescription drug from $13.50 per tablet to a reported $750.00 per tablet. The FDA-approved label for Daraprim indicates that it is prescribed for toxoplasmosis and other types of infections. Toxoplasmosis can be of major concern for patients with weakened immune systems such as patients with HIV/AIDS, pregnant women and children. According to the Centers for Disease Control and Prevention, pyrimethamine works to block folic acid synthesis in the parasite T. gondii, the cause of toxoplasmosis, and leucovorin helps to reverse the negative effects on bone marrow caused by this mechanism of action.

Imprimis is now offering customizable compounded formulations of pyrimethamine and leucovorin in oral capsules starting as low as $99.00 for a 100 count bottle, or at a cost of under a dollar per capsule. Compounded medications may be appropriate for prescription when a commercially-available medicine does not meet the specific needs of a patient. For ordering information, please visit

Mark L. Baum, CEO of Imprimis stated, "It is indisputable that generic drug prices have soared recently. While we have seen an increase in costs associated with regulatory compliance, recent generic drug price increases have made us concerned and caused us to take positive action to address an opportunity to help a needy patient population. While we respect Turing's right to charge patients and insurance companies whatever it believes is appropriate, there may be more cost-effective compounded options for medications, such as Daraprim, for patients, physicians, insurance companies and pharmacy benefit managers to consider. This is not the first time a sole supply generic drug – especially one that has been approved for use as long as Daraprim – has had its price increased suddenly and to a level that may make it unaffordable. In response to this recent case and others that we will soon identify, Imprimis is forming a new program called Imprimis Cares which is aligned to our corporate mission of making novel and customizable medicines available to physicians and patients today at accessible prices."

Mr. Baum added, "Today, some drug prices are simply out of control and we believe we may be able to help control costs by offering compounded alternatives to several sole source legacy generic drugs. Imprimis Cares and its team of compounding pharmacists will work with physicians and their patients to ensure they have affordable access to the medicines they need from the over 7,800 generic FDA-approved drugs. Imprimis Cares, available in all 50 states, will work with all third party insurers, pharmacy benefit managers and buying groups to offer its patient specific customizable compounded drug formulations at prices that ensure accessibility and that provide a reasonable profit for Imprimis. We are here to serve our patients and their physicians. We believe that when we do a great job serving our customers, our shareholders will also benefit."

Imprimis' finished compounded drug formulations do not have an FDA-approval label for recommended use. Imprimis compounded formulations are not FDA approved and may only be prescribed pursuant to a physician prescription for an individually identified patient consistent with federal and state laws governing compounded drug formulations.

Daraprim® is a registered trademark of Turing Pharmaceuticals LLC. Imprimis is not affiliated with Turing Pharmaceuticals LLC nor Daraprim®. Daraprim® is an FDA-approved drug. Please consult with your physician regarding which prescription options are most suitable for your specific needs.


San Diego-based Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY) is a national leader in the development, production and dispensing of novel compounded pharmaceuticals. The company's business primarily consists of four therapeutic segments including ophthalmology, urology, sinus and integrative medicine. Imprimis dispenses compounded pharmaceuticals in all 50 states from four facilities located in California, Texas, New Jersey and Pennsylvania. For more information about Imprimis, please visit the corporate website at

Common stock outstanding after the offering       8,391,172

Cash and cash equivalents                                            18,059,285


Cannabis Report
Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
#3141   BA! BOOM! BIATCH!! Stratdan 04/11/18 07:12:55 AM
#3140   Did You Not Hear Me? This Mother Come Stratdan 03/18/18 07:37:18 AM
#3139   * * $IMMY Video Chart 01-30-18 * * ClayTrader 01/30/18 05:19:55 PM
#3138   jumped in on the pullback to $1.94 Atlanta1 01/30/18 01:24:01 PM
#3137   Apparently IMMY is owned by fitbit. Whoda thunk? mkhazel 10/20/17 09:17:50 AM
#3136   * * $IMMY Video Chart 10-19-17 * * ClayTrader 10/19/17 05:24:06 PM
#3135   huge buying opportunity on this minor dip: Decimus1 10/19/17 02:24:33 PM
#3132   *Imprimis CEO Mark Baum Tells Benzinga Co. Will Decimus1 10/19/17 01:00:03 PM
#3131   Shares of Imprimis Pharmaceuticals Inc (NASDAQ: IMMY) got Decimus1 10/19/17 12:43:49 PM
#3130   high for the day is $2.79. Decimus1 10/19/17 11:10:29 AM
#3129   Out some 2.65 wow what a rush Awl416 10/19/17 09:55:54 AM
#3128   Thin to win wow Awl416 10/19/17 09:42:03 AM
#3127   Similar goingforittoday 06/24/17 02:47:39 PM
#3126   Longboard Capital Advisors, LLC has filed a new wiltonio 03/29/17 06:15:20 AM
#3125   Looks a lot like IMMY True Nature Expands Board, goingforittoday 02/28/17 10:32:33 AM
#3124 EmptyBones 02/05/17 06:35:50 PM
#3123   Any idea what these guys are doing now? BrazenBull 04/05/16 01:21:41 AM
#3122   Back in at 3.81 MasterBidder 02/12/16 01:36:06 PM
#3121   Sure did. trickledownfacists 12/17/15 05:36:13 PM
#3120   That Martin clown that jacked price on the MasterBidder 12/17/15 03:02:31 PM
#3119 ronk 12/10/15 11:57:39 AM
#3118   He just doesn't get it. Karma is gonna ronk 12/06/15 01:19:54 PM
#3117   Hey SG.. ronk 12/04/15 07:29:53 PM
#3116   So Imprimis used to be transdel pharmaceuticals... Was this Stock Guy777 12/04/15 06:57:48 PM
#3115   SA article from yesterday: ronk 12/03/15 09:52:51 AM
#3114   The Express Scripts news is really interesting. Back ronk 12/01/15 06:43:43 PM
#3113   Up big pm MasterBidder 12/01/15 09:15:11 AM
#3112   Great news! ronk 12/01/15 08:46:23 AM
#3111   Express Scripts Champions $1 per Pill Access to trickledownfacists 12/01/15 12:36:12 AM
#3110   6.66 maybe [SMART MONEY] 11/30/15 03:29:23 PM
#3109   Pricing come out? MasterBidder 11/30/15 03:11:55 PM
#3108   Nice start MasterBidder 11/30/15 09:34:44 AM
#3107   People want in. I bet we gap up Monday. Westorious 11/27/15 04:03:40 PM
#3106   That day it hit a low of 5. ronk 11/27/15 03:06:51 PM
#3105   Trade at 8.00 ah MasterBidder 11/27/15 02:34:18 PM
#3104   Yep :) MasterBidder 11/27/15 02:20:37 PM
#3103   Imagine if 5-10M volume comes in here [SMART MONEY] 11/27/15 02:11:22 PM
#3102   The dd is good on this one and MasterBidder 11/27/15 01:52:26 PM
#3101   NVISION Eye Centers Sign National Account Agreement for [SMART MONEY] 11/27/15 01:47:10 PM
#3100   Imprimis' Fight Against Martin Shkreli Is Part Of [SMART MONEY] 11/27/15 01:45:47 PM
#3099   Seriously. This new Turing pharm news is definitely helping. Westorious 11/27/15 01:41:30 PM
#3098   Thought it was only a matter of time ronk 11/27/15 01:17:09 PM
#3097   Big day MasterBidder 11/27/15 12:48:54 PM
#3096   I'll add through January. 503b in Feb. ronk 11/27/15 12:05:34 AM
#3095   I'm buying more shares tomorrow! Westorious 11/26/15 11:08:30 PM
#3094   Great piece about the trending compounding pharma industry: ronk 11/26/15 10:07:04 PM
#3093   Happy holiday, Westo! ronk 11/26/15 07:31:13 PM
#3092   That's a company I want to invest in. Westorious 11/26/15 07:16:23 PM
#3091   Thought the same. Imagine a company like IMMY ronk 11/26/15 07:00:42 PM
#3090   Good for us! Westorious 11/26/15 06:36:29 PM